Skip to content

Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates

Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03465501
Acronym
BOOST-CA
Enrollment
89
Registered
2018-03-14
Start date
2007-08-17
Completion date
2016-07-28
Last updated
2018-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal Canal Cancer

Keywords

Anal Canal Cancer, brachytherapy

Brief summary

Comparative retrospective study of two anal canal brachytherapy techniques aimed at boosting \[low dose rate (LDR) and high dose rate (HDR)\]

Detailed description

Efficacy of anal canal interstitial brachytherapy evaluated by local relapse rate, Tolerance of interstitial brachytherapy of the anal canal evaluated by the rate of chronic toxicities.

Interventions

RADIATIONBrachytherapy

Brachytherapy

Sponsors

Institut Paoli-Calmettes
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients treated by brachytherapy anal canal to boost.

Exclusion criteria

* Patients below age of 18 years

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of the efficacy of interstitial brachytherapy of the anal canal1 yearEfficacy of anal canal interstitial brachytherapy evaluated by local relapse rate
Evaluation of the tolerance of interstitial brachytherapy of the anal canal1 yearTolerance of interstitial brachytherapy of the anal canal evaluated by the rate of chronic toxicities.

Secondary

MeasureTime frameDescription
Estimation of local control1 yearLocal control defined as the time between the date of diagnosis and the date of local relapse or death or recent news
Estimation of disease free survival1 yearDisease free survival defined as the delay between the date of diagnosis and the date of local or locoregional or distant relapse or death or recent news
Estimation of overall survival1 yearOverall survival defined as the time between the date of diagnosis and the date of death or latest news
Comparison of the incidence of toxicities (CTCAE v4) between the 2 groups1 yearrate of toxicities

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026